It was a bit surprising that ONXX didn't even get a small bump on the Regorafenib approval for GIST. Maybe it came too soon on the heels for the big rise earlier in the week after the earnings report. In any event, it is nice to see that additional revenue will be coming into ONXX. With regards to Regorafenib, I am not sure what the time table is for its approval in Europe for either mCRC or GIST is, but that will be welcome news when it comes. Bayer also has Regorafenib in a large number of trials so more indication where it is efficacious may be coming down the line.